

# TRANSMITTAL FORM

Application Serial Number	10/694,629
Filing Date	October 27, 2003
First Named Inventor	Beausang
Group Art Unit	1648
Examiner Name	Ali Reza Salimi
Attorney Docket No.	MTP-012C4
Patent No.	Not applicable
Issue Date	Not applicable

## ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <ul style="list-style-type: none"> <li><input type="checkbox"/> Check Attached</li> <li><input type="checkbox"/> Copy of Fee Transmittal Form</li> </ul>	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences
<input type="checkbox"/> Amendment/Response <ul style="list-style-type: none"> <li><input type="checkbox"/> Preliminary</li> <li><input type="checkbox"/> After Final</li> <li><input type="checkbox"/> Affidavits/declaration(s)</li> <li><input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets _____]</li> </ul>	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Brief (in triplicate)
<input type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal	<input type="checkbox"/> Status Inquiry
<input checked="" type="checkbox"/> Information Disclosure Statement <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Form PTO-1449</li> <li><input type="checkbox"/> Copies of IDS Citations</li> </ul>	<input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input type="checkbox"/> Sequence Listing submission <ul style="list-style-type: none"> <li><input type="checkbox"/> Paper Copy/CD</li> <li><input type="checkbox"/> Computer Readable Copy</li> <li><input type="checkbox"/> Statement verifying identity of above</li> </ul>	<input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	<input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8
	<input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
	<input type="checkbox"/> CD(s) for large table or computer program	
	<input type="checkbox"/> Amendment After Allowance	
	<input type="checkbox"/> Request for Certificate of Correction <ul style="list-style-type: none"> <li><input type="checkbox"/> Certificate of Correction (in duplicate)</li> </ul>	

## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
 Goodwin Procter LLP  
 Exchange Place  
 Boston, MA 02109  
 Tel. No.: (617) 570-1000  
 Fax No.: (617) 523-1231  
 Customer No. 051414

## SIGNATURE BLOCK

Respectfully submitted,

  
 Brian R. Chase  
 Attorney for Applicants  
 Goodwin Procter LLP  
 Exchange Place  
 Boston, MA 02109




PATENT  
Attorney Docket No. MTP-012C4  
(120386/155992)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Beausang *et al.* CONFIRMATION NO.: 2617  
SERIAL NO.: 10/694,629 GROUP NO.: 1648  
FILING DATE: October 27, 2003 EXAMINER: Ali Reza Salimi  
TITLE: Nuclear Matrix Protein Fluid Assay

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 13th day of July, 2005.

  
\_\_\_\_\_  
Shawna Boudreau

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith is/are:

1. Transmittal Form (1 pg.);
2. Information Disclosure Statement (2 pgs.);
3. Form PTO-1449 (3 pg.); and
4. Return receipt postcard.

**PATENT**

Attorney Docket No. MTP-012C4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Beausang et al. CONFIRMATION NO: 2617  
SERIAL NO.: 10/694,629 GROUP NO.: 1648  
FILING DATE: October 27, 2003 EXAMINER: Ali Reza Salimi  
TITLE: Nuclear Matrix Protein Fluid Assay

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Each of the references were previously cited or made of record in U.S. Patent Application Serial No. 10/151,717 from which this application claims priority. Accordingly, pursuant to 37 C.F.R. § 1.98(d), Applicants have not supplied copies of the references cited on the attached Form PTO-1449, but shall do so upon request.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filings date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- the requisite Statement is below, OR

Information Disclosure Statement

Serial No. 10/694,629

Page 2 of 2

- the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**
  - the requisite Statement is below, **AND**
  - the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Brian R. Chase  
Attorney for Applicants  
Goodwin Procter, LLP  
Exchange Place  
Boston, Massachusetts 02109

Date: July 13, 2005  
Reg. No. 56,663

Tel. No.: (617) 570-1053  
Fax No.: (617) 523-1231

LIBC/2539949.1



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MTP-012C4

APPLICANT(S): Beausang *et al.*

SERIAL NO.: 10/694,629

FILING DATE: October 27, 2003

GROUP: 1648

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	4,628,027	12/86	Gay	435	7	
	A2	4,806,463	2/89	Goodchild <i>et al.</i>	435	5	
	A3	4,861,581	08/89	Epstein <i>et al.</i>	424	9	
	A4	4,882,268	11/89	Penman <i>et al.</i>	435	5	
	A5	4,885,236	12/89	Penman <i>et al.</i>	435	6	
	A6	4,937,185	06/90	Webb <i>et al.</i>	435	7	
	A7	5,017,474	5/91	McClune <i>et al.</i>	435	7.5	
	A8	5,032,508	07/91	Naughton <i>et al.</i>	435	32	
	A9	5,098,890	3/92	Gewirtz <i>et al.</i>	514	44	
	A10	5,273,877	12/93	Fey <i>et al.</i>	435	6	

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	B1	WO 87/03910	07/02/87	PCT				N	Y
	B2	WO 89/06697	7/89	PCT				N	Y
	B3	WO 91/17266	04/15/91	PCT				N	Y
	B4	EP 527941 B1	02/24/93	EPO				N	Y
	B5	WO 93/09437	05/13/93	PCT				N	Y

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C1	Compton <i>et al.</i> , "Identification of Novel Centromere/Kinetochore-associated Proteins Using Monoclonal Antibodies Generated Against Human Mitotic Chromosome Scaffolds," <i>J. Cell Biol.</i> , <u>112</u> (6):1083-1097 (1991).
EXAMINER		DATE CONSIDERED

<b>FORM PTO - 1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>		<b>ATTORNEY DOCKET NO.: MTP-012C4</b> <b>APPLICANT(S): Beausang <i>et al.</i></b> <b>SERIAL NO.: 10/694,629</b> <b>FILING DATE: October 27, 2003</b> <b>GROUP: 1648</b>
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>		
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>	
C2	Davidsohn (1974) Clinical Diagnosis By Laboratory Methods 15 <sup>th</sup> Ed., p. 864.	
C3	Domashenko <i>et al.</i> , "Comparison of the spectra of proteins synthesized in mouse thymocytes after irradiation or hydrocortisone treatment," <u>Int. J. Radiat. Biol.</u> , <u>57</u> (2):315-29 (1990).	
C4	Fey <i>et al.</i> , "Nuclear Matrix Proteins Reflect Cell Type of Origin in Cultured Human Cells," <u>Proc. Natl. Acad. Sci. USA</u> , <u>85</u> :121-125 (1988).	
C5	Fey <i>et al.</i> , "The Nuclear Matrix: Defining Structural and Functional Roles," <u>Critical Reviews in Euk. Gene Expression</u> , <u>1</u> (2):127-143 (1991).	
C6	Genetic Eng. News, "Matritech Announces First Product," Journal Announcement, July-Aug. <u>10</u> (7), p. 28.	
C7	Getzenberg <i>et al.</i> , "Tissue Specificity and Cell Death are Associated with Specific Alterations in Nuclear Matrix Proteins," Abstract published in the Journal of Urology, AUA Eighty-fifth Annual Meeting, May 13-17, 1990, 143: No. 4, Abstract No. 155 (1990).	
C8	Kallajoki <i>et al.</i> , "A 210 kD nuclear matrix protein is a functional part of the mitotic spindle; a microinjection study using SPN monoclonal antibodies," <u>EMBO J.</u> , <u>10</u> :3351-3362 (1991).	
C9	Keesee <i>et al.</i> , "Utilization of Nuclear Matrix Proteins for Cancer Diagnosis," <u>Critical Reviews in Eukaryotic Gene Expression</u> , <u>6</u> (2&3):189-214 (1996).	
C10	Köhler <i>et al.</i> , "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> , <u>256</u> :495-497 (1975).	
C11	Lerrick <i>et al.</i> , "Cytotoxic mechanism of tumor necrosis factor-α," <u>FASEB J.</u> , <u>4</u> : 3215-3223 (1990).	
C12	Lydersen <i>et al.</i> , "Human-Specific Nuclear Protein That Associates with the Polar Region of the Mitotic Apparatus: Distribution in a Human/Hamster Hybrid Cell," <u>Cell</u> , <u>22</u> :489-499 (1980).	
C13	Maekawa <i>et al.</i> , "Identification of a Minus End-Specific Microtubule-Associated Protein Located at the Mitotic Poles in Cultured Mammalian Cells," <u>European J. of Cell Biology</u> , <u>54</u> :255-267 (1991).	
C14	Miller <i>et al.</i> , "Detection of Nuclear Matrix Proteins in Serum from Cancer Patients," <u>Cancer Research</u> , <u>52</u> :422-427 (1992).	
C15	Miller <i>et al.</i> , "Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis," <u>Biotechniques</u> , <u>15</u> (6): 1042-1047 (1993) (Abstract).	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

<b>FORM PTO - 1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>		<b>ATTORNEY DOCKET NO.: MTP-012C4</b> <b>APPLICANT(S): Beausang <i>et al.</i></b> <b>SERIAL NO.: 10/694,629</b> <b>FILING DATE: October 27, 2003</b> <b>GROUP: 1648</b>
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>		
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>	
C16	Miller <i>et al.</i> , "Release of Nuclear Matrix Proteins during Apoptotic Cell Death," Abstract published in <u>J. Cell Biol.</u> , <u>115</u> : No. 3, Abstract No. 1822 (1991).	
C17	News Release, "Clinical Utility of Matritech's Bladder Cancer Test Reported in August Issue of Journal of Urology," (July 1996).	
C18	Nickerson <i>et al.</i> , "A Normally Masked Nuclear Matrix Antigen That Appears at Mitosis on Cytoskeleton Filaments Adjoining Chromosomes, Centrioles, and Midbodies," <u>J. Cell Biology</u> , <u>116</u> (4):977-987 (February 1992).	
C19	Oeller <i>et al.</i> , "Reversible Inhibition of Tomato Fruit Senescence by Antisense RNA," <u>Science</u> , <u>254</u> :437-439 (1991).	
C20	Scopes, R.K., <u>Protein Purification</u> , Springer-Venlag, New York, pp. 43-52 (1982).	
C21	Stuurman <i>et al.</i> , "A Monoclonal Antibody Recognizing Nuclear Matrix-Associated Nuclear Bodies," <u>J. Cell Science</u> , <u>101</u> :773-784 (1992).	
C22	Thibodeau <i>et al.</i> , "Monoclonal Antibody CC-3 Recognizes Phosphoproteins in Interphase and Mitotic Cells," <u>Experimental Cell Research</u> , <u>195</u> :145-153 (1991).	
C23	Todorov <i>et al.</i> , "Detection of the 125-kDa Nuclear Protein Mitotin in Centrosomes, the Poles of the Mitotic Spindle, and the Midbody," <u>Experimental Cell Research</u> , <u>199</u> :398-401 (1992).	
C24	Tousson <i>et al.</i> , "Centrophilin: A Novel Mitotic Spindle Protein Involved in Microtubule Nucleation," <u>J. Cell Biol.</u> , <u>112</u> (3):427-440 (1991).	
C25	Walker <i>et al.</i> , "Patterns of Cell Death," <u>Meth. Achiev. Exp. Pathol.</u> , <u>13</u> :18-54 (1988).	
C26	Weeks <i>et al.</i> , "Immunoassays Using Acridinium Esters," <u>Methods in Enzymology</u> , <u>133</u> :366-387 (1986).	
C27	Whitfield <i>et al.</i> , "Cloning of a Gene Encoding an Antigen Associated with the Centrosome in Drosophila," <u>J. Cell Science</u> , <u>89</u> :467-480 (1988).	
C28	Wyllie <i>et al.</i> , "Cell Death: The Significance of Apoptosis," <u>International Review of Cytol</u> , <u>68</u> :251-306 (1980)	
C29	Yang <i>et al.</i> , "The Nuclear-Mitotic Apparatus Protein is Important in the Establishment and Maintenance of the Bipolar Mitotic Spindle Apparatus," <u>Molecular Biology of the Cell</u> , <u>3</u> :1259-1267 (November 1992).	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>